It comes from stomach juice, it heals tendons, and you can take it orally for gut issues. Here's why BPC-157 became the most talked-about peptide in the research community.
Research context only. BPC-157 is not FDA-approved. All content is educational based on published research.
BPC-157 stands for Body Protection Compound 157. It's a synthetic pentadecapeptide — 15 amino acids — derived from a protein naturally found in human gastric juice. It was isolated and studied by Croatian researcher Dr. Predrag Sikiric and his team at the University of Zagreb, who noticed that gastric juice contained compounds with remarkable protective properties for the GI tract.
What started as gut research expanded significantly when animal studies revealed BPC-157's effects extended far beyond the stomach — it heals tendons, ligaments, muscles, nerves, and bones with unusual potency in preclinical models. It's now one of the most widely studied peptides in the research community.
The one-line version: BPC-157 is a piece of a stomach protein that, when injected or taken orally, appears to dramatically accelerate healing in multiple tissue types — particularly tendons, gut lining, and connective tissue. It's been called "the wolverine peptide" in research circles for the breadth of its healing activity.
BPC-157 upregulates VEGF and other growth factors that drive the formation of new blood vessels at repair sites. More vasculature means more oxygen and nutrients delivered to healing tissue.
BPC-157 interacts with the nitric oxide (NO) system — upregulating NO production in ways that support vascular repair and healing while downregulating inflammatory NO signaling. This dual effect is part of why it works across tissue types.
BPC-157 increases expression of EGF (epidermal growth factor), FGF (fibroblast growth factor), and other tissue-specific repair signals. These drive fibroblast proliferation, collagen synthesis, and tissue remodeling.
In the GI tract specifically, BPC-157 maintains and repairs the mucosal lining, protects against NSAID and alcohol-induced damage, and may modulate the gut-brain axis. This is its most extensively documented effect.
Oral vs injectable: BPC-157 is unusual among peptides in that it shows activity when taken orally for GI-specific effects. Oral administration gets degraded before reaching systemic circulation — so for tendon, muscle, or systemic healing, subcutaneous injection is required. For gut healing specifically, oral is a viable route.
BPC-157's research base is extensive by peptide standards. The Zagreb group has published dozens of animal studies covering tendon healing (including the highly challenging Achilles tendon model), gut mucosal repair, bone healing, nerve regeneration, and even antidepressant-like effects via dopamine and serotonin system modulation.
Notable research findings include: complete tendon-to-bone reattachment in severed Achilles tendon models, reversal of NSAID-induced gut damage, accelerated bone fracture healing, and neuroprotection in spinal cord injury models. The breadth is unusual — most peptides have a narrow therapeutic niche; BPC-157 seems to work across tissue types.
The human data gap: Despite extensive animal research and significant community use, BPC-157 has no completed human clinical trials. The Zagreb group has attempted to move it forward but regulatory and funding hurdles have kept it in preclinical territory. This is the legitimate uncertainty — the mechanism and animal data are compelling; the human data simply doesn't exist at scale yet.
BPC-157 has a notably clean safety profile in animal studies — no dose-limiting toxicities identified even at very high doses in rodent models. Reported issues in human research contexts:
The same VEGF/angiogenesis concern that applies to TB-500 applies here — theoretical risk in individuals with existing malignancies. Not demonstrated at research doses, but worth noting as a precaution.
The animal model results are impressive, but they're not instant and they're not universal. Healing timelines vary significantly by injury type, severity, and individual biology. Managing expectations is important — this is a research tool, not a magic compound.
Oral administration is only viable for GI-specific effects. The peptide gets broken down in the gut before reaching systemic circulation in meaningful concentrations. For tendon, muscle, or bone healing, subcutaneous injection is required.
Different peptide, different source, different primary mechanisms. TB-500 is systemic and works via actin/cell migration; BPC-157 is local-acting and works via growth factors and NO pathways. They complement each other rather than duplicate.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator